Brand names: Sorafenib Tosylate
4 interactions on record
Neomycin The concomitant use of sorafenib tablets with neomycin decreased the mean AUC of sorafenib, which may decrease the antitumor activity. Avoid concomitant use of sorafenib tablets with neomycin.
Source: FDA drug label - sorafenib
7.2 Inhibitors of CYP3A4 CYP3A4 inhibitors (e.g., ketoconazole, fluconazole, itraconazole, sorafenib, aprepitant, fosaprepitant, grapefruit, grapefruit juice) may decrease the metabolism of ifosfamide to its active alkylating metabolites, perhaps decreasing the effectiveness of ifosfamide treatment. 7.2 Inhibitors of CYP3A4 CYP3A4 inhibitors (e.g., ketoconazole, fluconazole, itraconazole, sorafenib, aprepitant, fosaprepitant, grapefruit, grapefruit juice) may decrease the metabolism of ifosfamide to its active alkylating metabolites, perhaps decreasing the effectiveness of ifosfamide treatment.
Source: FDA drug label - ifosfamide
Re gorafenib Clinical Impact: Regorafenib increased rosuvastatin exposure and may increase the risk of myopathy. I ntervention: In patients taking regorafenib, do not exceed a dose of EZALLOR SPRINKLE 10 mg once daily .
Source: FDA drug label - rosuvastatin
Re gorafenib Clinical Impact: Regorafenib increased rosuvastatin exposure and may increase the risk of myopathy. I ntervention: In patients taking regorafenib, do not exceed a dose of rosuvastatin 10 mg once daily .
Source: FDA drug label - rosuvastatin calcium